[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606280":3},{"organization":4,"outcomesModule":7,"designInfo":66,"detailedDescription":69,"studyPopulation":69,"armGroups":73,"interventions":84,"overallOfficials":69,"centralContacts":89,"locations":98,"responsibleParty":182,"collaborators":185,"id":190,"slug":69,"hasResults":191,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":191,"sex":196,"minAge":197,"maxAge":69,"enrollmentInfo":198,"targetDuration":69,"studyType":201,"phases":202,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":100,"whyStopped":69,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},{"fullName":5,"class":6},"Gelderse Vallei Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":60},[9],{"measure":10,"description":11,"timeFrame":12},"Glycaemic variability","The primary outcome is the mean glycaemic variability per 24 hours during the intervention, measured with Continuous Glucose Monitoring (CGM), expressed as the Coefficient of Variation (COV). The COV is calculated by dividing the standard deviation by the mean blood glucose level and multiplying by 100. It gives a relative measure of variability, which is helpful in comparing variability between individuals or groups with different mean glucose levels.","From enrollment to the end of the intervention at a maximum of 5 days.",[14,18,21,24,27,29,33,35,37,40,43,46,49,53,56],{"measure":15,"description":16,"timeFrame":17},"Glycaemic control","Assessed by mean and standard deviation of interstitial glucose concentrations and Mean Amplitude of Glycaemic Excursions (MAGE) (mmol\u002FL)","From enrollment to the end of the intervention at a maximum of 5 days",{"measure":19,"description":20,"timeFrame":17},"Insulin administred during intervention period","Insulin administred during intervention period (IU\u002Fday)",{"measure":22,"description":23,"timeFrame":17},"Dysglycemic events during intervention period","Number of hypoglycaemic events, defined as blood glucose level \\\u003C4.0 mmol\u002FL and number of hyperglycaemic events, defined as blood glucose level \\>10.0 mmol\u002FL",{"measure":25,"description":26,"timeFrame":12},"Gastrointestinal tolerance during the intervention period","Gastric residual volumes (mL), minimum, maximum and total volume per 24 hours.",{"measure":25,"description":28,"timeFrame":17},"Incidence of vomiting, diarrhoea, constipation and regurgitation during the intervetion periode",{"measure":30,"description":31,"timeFrame":32},"Circadian rhythm","Assessed by 24-hour curves of melatonin ( pg\u002FmL) in saliva.","Measured at day 1 and the end of the study period. End of the study period is day 5 of the study or earlier in case of: extubation, patient is no longer exclusively fed by gastric enteral nutrition or patient is discharged from ICU.",{"measure":30,"description":34,"timeFrame":32},"Assessed by 24-hour curves of cortisol( nmol\u002FL) in saliva.",{"measure":30,"description":36,"timeFrame":32},"Assessed by 24-hour curves of mRNA expression of essential clock genes (BMAL, CLOCK, Cry1 and Per2).",{"measure":38,"description":39,"timeFrame":32},"Body composition","Fat-free mass, fat mass and skeletal muscle mass (kg and %) by bio-electrical impendence analysis. This outcome is only measured in centres with the necessary equipment.",{"measure":41,"description":42,"timeFrame":32},"Muscle size","Cross-sectional area and muscle layer thickness of quadriceps muscle by ultrasonography. This outcome is only measured in centres with the necessary equipment.",{"measure":44,"description":45,"timeFrame":12},"Nutritional intake during intervention period","Total nutritional prescription and delivery per calendar day (energy in kJ\u002Fday, protein in g\u002Fday, fat in g\u002Fday and carbohydrate in g\u002Fday and % of total intake)",{"measure":47,"description":48,"timeFrame":17},"Non-nutritonal calories administred during intervention period","Non-nutritional calories delivered by propofol, glucose infusion, and citrate, delivery in kJ per calendar day",{"measure":50,"description":51,"timeFrame":52},"Health-related quality of life","Health-related quality of life measured with the 36-Item Short Form Health Survey (SF-36), 60 days after ICU admission","60 days after ICU admission",{"measure":54,"description":55,"timeFrame":52},"Sleep quality","Sleep quality measured with the Pittsburgh Sleep Quality Index (PSQI)",{"measure":57,"description":58,"timeFrame":59},"Glucoregulatory gastrointestinal hormones","GLP-1, C-peptide, insulin, and glucagon concentrations (mmol\u002FL). This outcome is only measured in the coordinating centre.","From 12:00 until 14:00 on the second study day.",[61,64],{"measure":62,"description":62,"timeFrame":63},"ICU length of stay","During index ICU stay, up to 60 days.",{"measure":65,"description":65,"timeFrame":63},"Days on mechanical ventilation",{"allocation":67,"interventionModel":68,"interventionModelDescription":69,"primaryPurpose":70,"observationalModel":69,"timePerspective":69,"maskingInfo":71},"RANDOMIZED","PARALLEL",null,"TREATMENT",{"masking":72,"maskingDescription":69,"whoMasked":69},"NONE",[74,78],{"label":75,"type":76,"description":77,"interventionNames":69},"Continuous enteral nutrition","NO_INTERVENTION","Participants will receive the standard of care, continuous enteral nutrition for 24 hours a day.",{"label":79,"type":80,"description":81,"interventionNames":82},"Intermittent enteral nutrition","EXPERIMENTAL","Participants will receive intermittent enteral nutrition in four separate portions between 8:00 a.m. and 8:00 p.m. Each portion will be administered over a one-hour period.",[83],"Other: Intermittent enteral nutrition",[85],{"type":6,"name":79,"description":81,"armGroupLabels":86,"otherNames":87},[79],[88],"Intermittent tube feeding",[90,95],{"name":91,"role":92,"phone":93,"phoneExt":69,"email":94},"Arthur RH van Zanten","CONTACT","+3131843115","ZantenA@zgv.nl",{"name":96,"role":92,"phone":69,"phoneExt":69,"email":97},"Imre WK Kouw","imre.kouw@wur.nl",[99,114,132,148,165],{"facility":5,"status":100,"city":101,"state":102,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":111,"contacts":112},"RECRUITING","Ede","Gelderland","6716 RP","Netherlands","NL",{"type":107,"coordinates":108},"Point",[109,110],5.65833,52.03333,{"lat":110,"lon":109},[113],{"name":91,"role":92,"phone":93,"phoneExt":69,"email":94},{"facility":115,"status":100,"city":116,"state":117,"zip":118,"country":104,"countryCode":105,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Deventer Ziekenhuis","Deventer","Overijssel","7416 SE",{"type":107,"coordinates":120},[121,122],6.16389,52.255,{"lat":122,"lon":121},[125,129],{"name":126,"role":92,"phone":127,"phoneExt":69,"email":128},"Arriette Kruisdijk-Gerritsen","0570535345","A.Gerritsen@dz.nl",{"name":130,"role":131,"phone":69,"phoneExt":69,"email":69},"Huub van den Oever","PRINCIPAL_INVESTIGATOR",{"facility":133,"status":100,"city":134,"state":117,"zip":135,"country":104,"countryCode":105,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Medisch Spectrum Twente","Enschede","7512KZ",{"type":107,"coordinates":137},[138,139],6.89583,52.21833,{"lat":139,"lon":138},[142,146],{"name":143,"role":92,"phone":144,"phoneExt":69,"email":145},"Martin Rinket","+31650883330","M.Rinket@mst.nl",{"name":147,"role":131,"phone":69,"phoneExt":69,"email":69},"Bert Beishuizen",{"facility":149,"status":100,"city":150,"state":151,"zip":152,"country":104,"countryCode":105,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Martini Ziekenhuis","Groningen","Provincie Groningen","9728NT",{"type":107,"coordinates":154},[155,156],6.56667,53.21917,{"lat":156,"lon":155},[159,163],{"name":160,"role":92,"phone":161,"phoneExt":69,"email":162},"Kristine Koekkoek, Dr.","0505245245","kristine.koekkoek@mzh.nl",{"name":164,"role":131,"phone":69,"phoneExt":69,"email":69},"Kristine Koekkoek",{"facility":166,"status":100,"city":167,"state":168,"zip":169,"country":104,"countryCode":105,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Haga Ziekenhuis","The Hague","South Holland","2545 AA",{"type":107,"coordinates":171},[172,173],4.29861,52.07667,{"lat":173,"lon":172},[176,180],{"name":177,"role":92,"phone":178,"phoneExt":69,"email":179},"Lettie van den Berg","070-2108884","A.E.vandenBerg@hagaziekenhuis.nl",{"name":181,"role":131,"phone":69,"phoneExt":69,"email":69},"Thomas Ottens",{"type":131,"investigatorFullName":183,"investigatorTitle":184,"investigatorAffiliation":5,"oldNameTitle":69,"oldOrganization":69},"ARH van Zanten, MD PhD","Internist-intensivist, Medical Head of ICU and Research",[186,188],{"name":187,"class":6},"ZonMw: The Netherlands Organisation for Health Research and Development",{"name":189,"class":6},"Wageningen University and Research","100606280",false,"NCT07173504","The Effect of Continuous Versus Intermittent Enteral Nutrition on Metabolic Outcomes in Critically Ill Patients","CONVEnIENT","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Receiving or eligible to receive exclusively gastric tube feeding;\n3. Expected ICU stay ≥48 hours;\n4. Receiving or anticipated to receive invasive mechanical ventilation within 48 hours after ICU admission.\n\nExclusion Criteria:\n\n1. The treating clinician considers participation in the study clinically contraindicated (e.g., change in feeding regimen, no possibility for placement of CGM on arms, not able to receive exclusive gastric tube feeding);\n2. Death is deemed to be imminent or inevitable during admission, and the attending doctor, patient, or substitute decision-maker is not committed to active treatment;\n3. Pregnancy;\n4. Expected fasting for ≥12 hours during the study period, for example, due to medical procedures;\n5. Readmission in last 14 days;\n6. Patients with burn injuries;\n7. Participating in another nutritional intervention study.","ALL","18 Years",{"count":199,"type":200},124,"ESTIMATED","INTERVENTIONAL",[203],"NA","The goal of this clinical trial is to investigate the effect of continuous versus intermittent enteral nutrition on metabolic outcomes in critically ill adult patients.\n\nThe aim of this study is to:\n\n• To assess the effect of a daytime intermittent tube feeding pattern compared to standard continuous tube feeding on glycaemic control, gastrointestinal function, gastrointestinal hormones, markers of sleep quality and circadian rhythm, and lean body mass and body composition.\n\nParticipants will receive either continuous enteral nutrition for 24 hours a day or intermittent enteral nutrition during the day, consisting of 4 portions each administered over 1 hour between 8 am and 8 pm. The maximum duration of the intervention is 5 days or until participants do not receive exclusive gastric enteral nutrition.",[206],"Critical Illness",[208,209,210,211],"critical illness","tube feeding","glycemic control","chrononutrition","2026-03-11",{"date":214,"type":215},"2026-03-13","ACTUAL",{"date":217,"type":215},"2025-09-30",{"date":219,"type":200},"2028-09",{"name":5,"class":6},5]